eli lilly sues compounders for selling unapproved copies of tirzepatide Compounding group FDA removing obesity drug from shortages list Lilly sues two medical spas

These findings have important implications on developing host-targeted therapeutics as a novel antibacterial strategy

Related Reading Glp 1 Receptor Agonists For Weight Loss Glp 1 For Weight Loss 2 Glp 1 Weight Loss Before And After Glp 1 Dosage For Weight Loss Medical and Editorial Standards Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims

Controlled room temperature protects medication stability during storage

Dynamic and nuclear expression of PDGFRalpha and IGF-1R in alveolar Rhabdomyosarcoma

Food and Drug Administration (FDA) has recently intensified its oversight of compounded GLP-1 receptor agonists, specifically semaglutide and tirzepatide, which are commonly used for weight loss treatments